They reported that in 26 MASLD patients with advanced fibrosis, LCAT protein mass was decreased (0.19 ± 0.10 vs 0.14 ± 0.04 mol/mol apo AI) [14]. This evidence concerns the gene AOPEP and metabolic dysfunction-associated steatotic liver disease.